Cargando…
Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide. Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma (PDAC) and numerous potential mechanisms have been demonstrated but much remains to be understood. To overcome the existing limitations in...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797580/ https://www.ncbi.nlm.nih.gov/pubmed/31475468 http://dx.doi.org/10.1002/cam4.2384 |
_version_ | 1783459859174260736 |
---|---|
author | Luo, Wenhao Yang, Gang Qiu, Jiangdong Luan, Jingyang Zhang, Ying You, Lei Feng, Mengyu Zhao, Fangyu Liu, Yueze Cao, Zhe Zheng, Lianfang Zhang, Taiping Zhao, Yupei |
author_facet | Luo, Wenhao Yang, Gang Qiu, Jiangdong Luan, Jingyang Zhang, Ying You, Lei Feng, Mengyu Zhao, Fangyu Liu, Yueze Cao, Zhe Zheng, Lianfang Zhang, Taiping Zhao, Yupei |
author_sort | Luo, Wenhao |
collection | PubMed |
description | Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide. Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma (PDAC) and numerous potential mechanisms have been demonstrated but much remains to be understood. To overcome the existing limitations in PC treatment, newer approaches targeting intrinsic or acquired mechanisms have been found to improve drug therapeutic effectiveness in PC patients. Here, we provide an update of the most recent findings and their implications for clinicians, and attempt to summarize the various aspects of different individualized novel therapies for PC that could most benefit metastatic PDAC patients. |
format | Online Article Text |
id | pubmed-6797580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67975802019-10-21 Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? Luo, Wenhao Yang, Gang Qiu, Jiangdong Luan, Jingyang Zhang, Ying You, Lei Feng, Mengyu Zhao, Fangyu Liu, Yueze Cao, Zhe Zheng, Lianfang Zhang, Taiping Zhao, Yupei Cancer Med Cancer Prevention Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide. Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma (PDAC) and numerous potential mechanisms have been demonstrated but much remains to be understood. To overcome the existing limitations in PC treatment, newer approaches targeting intrinsic or acquired mechanisms have been found to improve drug therapeutic effectiveness in PC patients. Here, we provide an update of the most recent findings and their implications for clinicians, and attempt to summarize the various aspects of different individualized novel therapies for PC that could most benefit metastatic PDAC patients. John Wiley and Sons Inc. 2019-09-01 /pmc/articles/PMC6797580/ /pubmed/31475468 http://dx.doi.org/10.1002/cam4.2384 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Prevention Luo, Wenhao Yang, Gang Qiu, Jiangdong Luan, Jingyang Zhang, Ying You, Lei Feng, Mengyu Zhao, Fangyu Liu, Yueze Cao, Zhe Zheng, Lianfang Zhang, Taiping Zhao, Yupei Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? |
title | Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? |
title_full | Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? |
title_fullStr | Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? |
title_full_unstemmed | Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? |
title_short | Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? |
title_sort | novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: how far are we from the destination? |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797580/ https://www.ncbi.nlm.nih.gov/pubmed/31475468 http://dx.doi.org/10.1002/cam4.2384 |
work_keys_str_mv | AT luowenhao noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT yanggang noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT qiujiangdong noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT luanjingyang noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT zhangying noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT youlei noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT fengmengyu noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT zhaofangyu noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT liuyueze noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT caozhe noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT zhenglianfang noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT zhangtaiping noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination AT zhaoyupei noveldiscoveriestargetinggemcitabinebasedchemoresistanceandnewtherapiesinpancreaticcancerhowfararewefromthedestination |